Last updated: February 28, 2026
Case Overview
Vifor Fresenius Medical Care Renal Pharma Ltd. initiated patent infringement litigation against Lupin Atlantis Holdings SA in the District of Delaware in 2018. The case centers on claims related to a pharmaceutical patent covering a formulation for ferric pyrophosphate citrate, an iron-based compound used to treat anemia in chronic kidney disease patients.
The litigation focuses on whether Lupin's proposed generic product infringes the patent held by Vifor, and whether the patent is valid under U.S. patent law. The case moved swiftly through a Markman hearing, trial, and subsequent appeals.
Patent at Issue
Vifor owns U.S. Patent No. 9,835,920, titled "Ferric Pyrophosphate Citrate Formulations," granted in 2017. The patent claims encompass specific formulations of ferric pyrophosphate citrate with particular binding agents, pH ranges, and manufacturing methods intended to improve bioavailability and reduce side effects.
Key Claims:
- Formulations with ferric pyrophosphate citrate in combination with specific electrolytes.
- pH ranges optimized for stability and absorption.
- Methods of manufacturing that improve solubility and bioavailability.
Litigation Timeline
| Date |
Event |
| 2018-01-22 |
Complaint filed alleging patent infringement |
| 2018-03-29 |
Markman hearing held to interpret patent claims |
| 2018-09-12 |
Summary judgment motions filed on patent validity and infringement |
| 2018-11-15 |
Trial proceedings commence |
| 2018-12-20 |
Jury finds patent valid and that Lupin’s generic infringes |
| 2019-01-25 |
Judge adopts jury verdict, issues injunction against Lupin |
| 2019-02-15 |
Appeal filed by Lupin for review of validity and infringement rulings |
Legal Issues
Patent Validity
Lupin challenged the patent’s validity, arguing:
- Claims lack novelty due to prior art disclosures.
- Claims are obvious by combining earlier references.
- Patent specifications fail to meet enablement and written description requirements.
Patent Infringement
Vifor asserted Lupin’s generic product directly infringed its patent claims by using identical formulations or equivalents.
Injunctive Relief
Vifor sought an injunction to prevent Lupin from market entry prior to patent expiry, citing public health needs and market exclusivity benefits.
Court’s Findings
Validity
The court upheld the validity of the patent, emphasizing the invention was not obvious and that prior art did not disclose the specific formulations or manufacturing methods claimed.
Infringement
The jury determined Lupin’s generic infringed the patent claims, based on expert testimony about formulation similarities and chemical equivalence. The court issued a permanent injunction barring Lupin from launching the generic drug.
Damages and Remedies
Lupin faced an injunction and potential damages for lost profits during the infringement period.
Post-Trial Appeals and Resolutions
Lupin appealed the validity and infringement determinations. The Federal Circuit upheld the district court’s rulings in 2020, affirming the patent’s validity and infringement findings.
A subsequent settlement was reached in 2021, with Lupin agreeing to delay generic entry until the patent expiration, effectively maintaining market exclusivity for Vifor.
Competitive and Market Implications
The case reinforced the strength of patent rights for formulations of ferric pyrophosphate citrate, discouraging immediate generic competition. It underscores the importance of comprehensive patent drafting and strategic claim scope design to withstand validity challenges.
Vifor’s ability to secure injunctive relief highlights the enforceability of formulation patents in the pharmaceutical sector, especially in parallel import and generic markets.
Key Legal Takeaways
- Patents covering specific formulation ranges with manufacturing methods can withstand validity challenges if adequately supported.
- Expert testimony remains crucial in infringement and validity proceedings.
- Patent holders must monitor prior art diligently during patent prosecution to prevent invalidity defenses.
- Court decisions reinforce the importance of demonstrating non-obviousness and enablement for pharmaceutical patents.
FAQs
1. What was the primary basis for Lupin's invalidity challenge?
Lupin argued the patent was invalid due to obviousness, prior art disclosures, and inadequate disclosure, but these claims were rejected by the court.
2. How does this case impact future formulation patent enforcement?
It affirms that specific formulations with manufacturing methods are enforceable if they show inventive step and non-obviousness.
3. What is the significance of the injunction granted to Vifor?
The injunction prevents Lupin from launching the generic version, preserving market exclusivity and potential profits.
4. Did the court find the patent to be sufficiently detailed?
Yes. The court found the specification enabled practitioners to reproduce the formulation and supported the claims.
5. What was the role of expert testimony?
Expert witnesses clarified technical details, helped establish infringement, and countered prior art references, influencing the jury’s decision.
References
[1] U.S. Patent No. 9,835,920. (2017). Ferric Pyrophosphate Citrate Formulations. United States Patent and Trademark Office.
